Documentos relacionados

1. Citalopram and Cannabidiol: In Vitro and In Vivo Evidence of Pharmacokinetic Interactions Relevant to the Treatment of Anxiety Disorders in Young People.
2. Biotransformation of 4-fluoro-N-(1-{2-[(propan-2-yl)phenoxy]ethyl}-8-azabicyclo[3.2.1]octan-3-yl)-benzenesulfonamide, a novel potent 5-HT₇ receptor antagonist with antidepressant-like and anxiolytic properties: In vitro and in silico approach.
3. Selegiline transdermal system: an examination of the potential for CYP450-dependent pharmacokinetic interactions with 3 psychotropic medications.
4. Pharmacology of basimglurant (RO4917523, RG7090), a unique metabotropic glutamate receptor 5 negative allosteric modulator in clinical development for depression.
5. On the practical aspects of characterising monoamine oxidase inhibition in vitro.
6. Antidepressant treatments in children and adolescents. I. Affective disorders.
7. Withdrawal and discontinuation phenomena associated with tranylcypromine: a systematic review.
8. New 2-Pyrazoline and Hydrazone Derivatives as Potent and Selective Monoamine Oxidase A Inhibitors.
9. Design, synthesis and evaluation of activity and pharmacokinetic profile of new derivatives of xanthone and piperazine in the central nervous system.
10. The pharmacology of reversible monoamine oxidase inhibitors.